The goal of this study is evaluation of the Montelukast and Prednisone therapeutic effect simultaneously in patients with Oral Lichen Planus (OLP). If this research will be successful, we can reduce corticosteroid dosage, and decrease its side effects. In addition, we can achieve desirable consequences with low adverse effects of Montelukast. Two hundreds patients with erosive oral lichen planus (middle aged males and females) will be selected and diagnosis of all patients will be carried out by clinical sings and biopsy. Inclusion criteria: (1) Diagnosis of OLP will be carried out by clinical history, physical exams and histopathological findings. (2) All of the patients should not use medication for at least two months. (3) They should not have systemic diseases such as diabetes mellitus, hepatitis and trauma history. Exclusion criteria : Patient is non-compliant with treatment until end of study. In this randomized double blinded study ( the practitioner and patient do not know the therapeutic process) , the patients divided into two groups randomly ; Group A : daily 20 milligrams (mg) oral Prednisone for 15 days and then 12.5 mg for 15 days and 6.25 mg alternate day for 15 days . Group B : Prednisone similar to group A and 10 mg oral Montelukast daily for first month and then 10 mg Montelukast alternate day for second month. For patients in group A, as well as Prednisone, placebo will be prescribed similar to Montelukast and with same administration. The lesion size with ruler or flexible surgical probe and pain quantity with Visual Analogue Scaling (VAS) will be recorded before treatment and every 2 weeks after treatment for 3 months. Failure of treatment will been defined with lack of clinical improvement for at least three months period.
One hundred patients with erosive oral lichen planus (middle aged males and females) will be selected and diagnosis of all patients will be carried out by clinical sings and biopsy. Inclusion criteria: (1) Diagnosis of OLP will be carried out by clinical history, physical exams and histopathological findings. (2) All of the patients should not use medication for at least two months. (3) They should not have systemic diseases such as diabetes mellitus, hepatitis and trauma history. Exclusion criteria : Patient is non-compliant with treatment until end of study.
In this randomized single blinded study (only the practitioner knows the therapeutic process) , the patients divided into two groups randomly ; Group A : daily 20 milligrams (mg) oral Prednisone for 15 days and then 12.5 mg for 15 days and 6.25 mg alternate day for 15 days . Group B : Prednisone similar to group A and 10 mg oral Montelukast daily for first month and then 10 mg Montelukast alternate day for second month. For patients in group A, as well as Prednisone, placebo will be prescribed similar to Montelukast and with same administration. The lesion size with ruler or flexible surgical probe and pain quantity with Visual Analogue Scaling (VAS) will be recorded before treatment and every 2 weeks after treatment for 3 months. Failure of treatment will been defined with lack of clinical improvement for at least three months period.